Conclusions: AMPYRA
(Dalfampridine-ER) was associated with short-term improvements in
walking speed and community participation, and sustained improvements in
walking endurance and self-perceived impact of MS on walking for one
year. Our study supports the utility of Ampyra in late MS.
Objectives: The objective of this paper is to determine the
clinical tolerability and effects of dalfampridine on walking and
community participation.
Methods: All patients
at the Portland VA Medical Center prescribed dalfampridine-ER over one
year completed the Timed 25-Foot Walk, Multiple Sclerosis Walking Scale-12, Two-Minute Timed Walk, and Community Integration
Questionnaire
(CIQ) at baseline and follow-up clinic visits.
Multiple Sclerosis Journal. published 7 October 2013,10.1177/1352458513507356
Michelle
H. Cameron, Oregon Health and Science University and Portland VA
Medical Center, 3181 SW Sam Jackson Park Road, L226, Portland, OR 97219,
USA. Email: cameromi@ohsu.edu
READ FULL STORY
